Regional Blue Cross Blue Shield plan will
cover non-invasive screening of esophageal precancer and
cancer
NEW
YORK, March 13, 2025 /PRNewswire/
-- Lucid Diagnostics Inc. (Nasdaq:
LUCD) ("Lucid" or the "Company"), a commercial-stage,
cancer prevention medical diagnostics company and subsidiary of
PAVmed Inc. (Nasdaq: PAVM), today announced that Highmark Blue
Cross Blue Shield, an independent licensee of the Blue Cross and
Blue Shield Association, has issued a positive coverage policy for
non-invasive screening of esophageal precancer and cancer in
New York state. The new policy
will cover Lucid's EsoGuard® Esophageal DNA Test in
patients who meet established criteria for esophageal precancer
testing consistent with professional society guidelines.
"This positive policy coverage decision by a commercial insurer
is a landmark event for Lucid," said Lishan
Aklog, M.D., Lucid's Chairman and Chief Executive Officer.
"We believe that this decision will serve as a precedent to drive
positive policy coverage decisions from other commercial insurers
and further validates the strength of our clinical evidence base.
We remain deeply engaged with commercial insurers across the
country as we seek to expand access to EsoGuard precancer
testing."
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention
medical diagnostics company, and subsidiary of (Nasdaq: PAVM).
Lucid is focused on the millions of patients with gastroesophageal
reflux disease (GERD), also known as chronic heartburn, who are at
risk of developing esophageal precancer and cancer. Lucid's
EsoGuard® Esophageal DNA Test, performed on samples
collected in a brief, noninvasive office procedure with its
EsoCheck® Esophageal Cell Collection Device, represent
the first and only commercially available tools designed with the
goal of preventing cancer and cancer deaths through widespread,
early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of Lucid's management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of Lucid's common stock; general economic and market
conditions; the uncertainties inherent in research and development,
including the cost and time required to advance Lucid's products to
regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from Lucid's clinical and
preclinical studies; whether and when Lucid's products are cleared
by regulatory authorities; market acceptance of Lucid's products
once cleared and commercialized; Lucid's ability to raise
additional funding as needed; and other competitive developments.
In addition, Lucid continues to monitor the COVID-19 pandemic and
the pandemic's impact on Lucid's businesses. These factors are
difficult or impossible to predict accurately and many of them are
beyond Lucid's control. In addition, new risks and uncertainties
may arise from time to time and are difficult to predict. For a
further list and description of these and other important risks and
uncertainties that may affect Lucid's future operations, see Part
I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, as the
same may be updated in Part II, Item 1A, "Risk Factors" in any
Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its
most recent Annual Report. Lucid disclaims any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-secures-first-positive-commercial-insurance-coverage-policy-for-its-esoguard-esophageal-dna-test-302400977.html
SOURCE Lucid Diagnostics
